VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below 200 Day Moving Average – Here’s Why

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.55 and traded as low as $0.61. VistaGen Therapeutics shares last traded at $0.6249, with a volume of 655,298 shares changing hands.

Wall Street Analysts Forecast Growth

VTGN has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Stock Down 4.0%

The stock has a market cap of $24.76 million, a P/E ratio of -0.33 and a beta of 0.31. The stock has a fifty day simple moving average of $0.60 and a 200-day simple moving average of $1.55.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.14 million. Sell-side analysts anticipate that VistaGen Therapeutics, Inc. will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. AdvisorShares Investments LLC grew its stake in VistaGen Therapeutics by 1.9% during the third quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock worth $735,000 after purchasing an additional 3,884 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics during the first quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics during the third quarter worth approximately $39,000. Boothbay Fund Management LLC grew its stake in VistaGen Therapeutics by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after purchasing an additional 19,166 shares during the period. Finally, Bank of America Corp DE grew its stake in VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.